Ooi JY - Search Results

1

miRNA therapeutics: a new class of drugs with potential therapeutic applications in the heart.

Bernardo BC, Ooi JY, Lin RC, McMullen JR. Bernardo BC, et al. Among authors: ooi jy. Future Med Chem. 2015;7(13):1771-92. doi: 10.4155/fmc.15.107. Epub 2015 Sep 24. Future Med Chem. 2015. PMID: 26399457 Review.

2

The therapeutic potential of miRNAs regulated in settings of physiological cardiac hypertrophy.

Ooi JY, Bernardo BC, McMullen JR. Ooi JY, et al. Future Med Chem. 2014 Feb;6(2):205-22. doi: 10.4155/fmc.13.196. Future Med Chem. 2014. PMID: 24467244 Review.

3

Silencing of miR-34a attenuates cardiac dysfunction in a setting of moderate, but not severe, hypertrophic cardiomyopathy.

Bernardo BC, Gao XM, Tham YK, Kiriazis H, Winbanks CE, Ooi JY, Boey EJ, Obad S, Kauppinen S, Gregorevic P, Du XJ, Lin RC, McMullen JR. Bernardo BC, et al. Among authors: ooi jy. PLoS One. 2014 Feb 27;9(2):e90337. doi: 10.1371/journal.pone.0090337. eCollection 2014. PLoS One. 2014. PMID: 24587330 Free PMC article.

4

Therapeutic silencing of miR-652 restores heart function and attenuates adverse remodeling in a setting of established pathological hypertrophy.

Bernardo BC, Nguyen SS, Winbanks CE, Gao XM, Boey EJ, Tham YK, Kiriazis H, Ooi JY, Porrello ER, Igoor S, Thomas CJ, Gregorevic P, Lin RC, Du XJ, McMullen JR. Bernardo BC, et al. Among authors: ooi jy. FASEB J. 2014 Dec;28(12):5097-110. doi: 10.1096/fj.14-253856. Epub 2014 Aug 21. FASEB J. 2014. PMID: 25145628

5

Pathophysiology of cardiac hypertrophy and heart failure: signaling pathways and novel therapeutic targets.

Tham YK, Bernardo BC, Ooi JY, Weeks KL, McMullen JR. Tham YK, et al. Among authors: ooi jy. Arch Toxicol. 2015 Sep;89(9):1401-38. doi: 10.1007/s00204-015-1477-x. Epub 2015 Feb 24. Arch Toxicol. 2015. PMID: 25708889 Review.

6

Identification of miR-34 regulatory networks in settings of disease and antimiR-therapy: Implications for treating cardiac pathology and other diseases.

Ooi JYY, Bernardo BC, Singla S, Patterson NL, Lin RCY, McMullen JR. Ooi JYY, et al. RNA Biol. 2017 May 4;14(5):500-513. doi: 10.1080/15476286.2016.1181251. Epub 2016 Apr 28. RNA Biol. 2017. PMID: 27124358 Free PMC article.

7

Translational Potential of Non-coding RNAs for Cardiovascular Disease.

Ooi JYY, Bernardo BC. Ooi JYY, et al. Adv Exp Med Biol. 2020;1229:343-354. doi: 10.1007/978-981-15-1671-9_21. Adv Exp Med Biol. 2020. PMID: 32285423 Review.

8

Sex differences in response to miRNA-34a therapy in mouse models of cardiac disease: identification of sex-, disease- and treatment-regulated miRNAs.

Bernardo BC, Ooi JY, Matsumoto A, Tham YK, Singla S, Kiriazis H, Patterson NL, Sadoshima J, Obad S, Lin RC, McMullen JR. Bernardo BC, et al. Among authors: ooi jy. J Physiol. 2016 Oct 15;594(20):5959-5974. doi: 10.1113/JP272512. Epub 2016 Jul 20. J Physiol. 2016. PMID: 27270487 Free PMC article.

9

The small-molecule BGP-15 protects against heart failure and atrial fibrillation in mice.

Sapra G, Tham YK, Cemerlang N, Matsumoto A, Kiriazis H, Bernardo BC, Henstridge DC, Ooi JY, Pretorius L, Boey EJ, Lim L, Sadoshima J, Meikle PJ, Mellet NA, Woodcock EA, Marasco S, Ueyama T, Du XJ, Febbraio MA, McMullen JR. Sapra G, et al. Among authors: ooi jy. Nat Commun. 2014 Dec 9;5:5705. doi: 10.1038/ncomms6705. Nat Commun. 2014. PMID: 25489988 Free article.

10

Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling.

McMullen JR, Boey EJ, Ooi JY, Seymour JF, Keating MJ, Tam CS. McMullen JR, et al. Among authors: ooi jy. Blood. 2014 Dec 11;124(25):3829-30. doi: 10.1182/blood-2014-10-604272. Blood. 2014. PMID: 25498454 Free article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

39 results

Search Page